Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

Antonia Sambola, MD; Julio Osende, MD; James Hathcock, PhD; Michael Degen, BSc; Yale Nemerson, MD; Valentin Fuster, MD, PhD; Jill Crandall, MD; Juan Jose Badimon, PhD

Background—Several studies suggest a role for an increased circulating pool of tissue factor (TF) in atherothrombotic diseases. Furthermore, certain cardiovascular risk factors, such as diabetes, hyperlipemia, and smoking, are associated with a higher incidence of thrombotic complications. We hypothesized that the observed increased blood thrombogenicity (BT) observed in patients with type 2 diabetes mellitus may be mediated via an increased circulating tissue factor activity. We have extended our study to smokers and hyperlipidemic subjects.

Methods and Results—Poorly controlled patients with type 2 diabetes mellitus (n=36), smokers (n=10), and untreated hyperlipidemic subjects (n=10) were studied. Circulating TF was immunocaptured from plasma, relipidated, and quantified by factor Xa (FXa) generation in the presence of factor VIIa. BT was assessed as thrombus formation on the Badimon perfusion chamber. Patients with improvement in glycemic control showed a reduction in circulating TF (362±135 versus 243±74 pmol/L per min FXa, P=0.0001). A similar effect was observed in BT (15 445±1130 versus 12 072±596 μm/mm², P=0.01). Two hours after smoking 2 cigarettes, TF was increased (217±72 versus 283±106 pmol/L per min FXa, P=0.003). Hyperlipidemic subjects showed higher TF (237±63 versus 195±44 pmol/L per min FXa, P=0.035) than healthy volunteers.

Conclusions—These findings suggest that high levels of circulating TF may be the mechanism of action responsible for the increased thrombotic complications associated with the presence of these cardiovascular risk factors. These observations strongly emphasize the usefulness of the management of the patients based on their global risk assessment.

(Circulation. 2003;107:973-977.)

Key Words: cardiovascular diseases ▪ risk factors ▪ thrombosis ▪ coagulation

Tissue factor (TF) is considered to be a major regulator of normal hemostasis and thrombosis.1-2 TF is highly expressed in atherosclerotic plaques, and its content has been related to plaque thrombogenicity.3-9 Recent evidence suggests the existence of a blood-borne pool of TF that may play a critical role in the propagation of thrombosis.10,11 Moreover, it has been reported that polymorphonuclear leukocytes might be involved in the transport of circulating TF to platelets by a CD15-dependent mechanism.12 High plasma levels of TF antigen have been reported in patients with acute coronary syndromes (ACS) versus patients with stable angina or non-coronary artery disease.13 Furthermore, circulating TF-positive microparticles with procoagulant activity have been described in patients with ACS.14,15 It is well established that atherosclerotic lesion disruption and subsequent acute thrombus formation play a key role in ~70% of patients dying from an ACS.16-18 Risk factors such as diabetes mellitus type 2 (DMT2), hypercholesterolemia, and smoking have been known to exacerbate the progression of atherosclerotic disease and trigger atherothrombotic complications.17,18 The presence of these risk factors seems to play a critical role in patients who die from cardiovascular causes while having only plaque erosion, and this suggests that an increased blood thrombogenicity (BT) combined with endothelial erosion is capable of triggering an ACS event in the absence of more severe plaque disruption.19,20 These observations seem to highlight not only the pathological role of the lipid-rich vulnerable plaque but also the role of increased BT (high-risk "vulnerable" blood) in the pathogenesis of ACS.

Our data indicate that the described hyperthrombotic or procoagulant state responsible for the increased rate of atherothrombotic complications among diabetic, hyperlipemic, and smoker populations could be mediated via increased levels of circulating TF.

Methods

Study Population
The present study involved 3 different populations: T2DM patients (n=36) from a previously published study,21 subjects (n=10) who...
TABLE 1. Clinical Characteristics at Baseline in the Diabetes Study

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control</th>
<th>T2DM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male</td>
<td>7/8</td>
<td>15/21</td>
</tr>
<tr>
<td>Age, y</td>
<td>54±14</td>
<td>57±8</td>
</tr>
<tr>
<td>Diabetes duration</td>
<td>NA</td>
<td>11±9</td>
</tr>
<tr>
<td>Smoking</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>88±13</td>
<td>164±50</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>189±27</td>
<td>194±35</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>123±26</td>
<td>121±28</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>44±11</td>
<td>46±11</td>
</tr>
<tr>
<td>Statins</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Aspirin</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>3</td>
<td>14</td>
</tr>
<tr>
<td>Blood thrombogenicity</td>
<td>11 354±570</td>
<td>14 389±762*</td>
</tr>
<tr>
<td>Tissue factor activity</td>
<td>216±35</td>
<td>371±161*</td>
</tr>
</tbody>
</table>

*p<0.01; **p=0.001.

TABLE 2. Demographic Characteristics of the Smokers and Hyperlipidemic Groups and Respective Controls

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control</th>
<th>Smoker Group</th>
<th>Hyperlipidemic Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male</td>
<td>5/5</td>
<td>6/4</td>
<td>4/6</td>
</tr>
<tr>
<td>Age, y</td>
<td>32±10</td>
<td>31±10</td>
<td>49±11</td>
</tr>
<tr>
<td>Smoking</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>176±18</td>
<td>180±8</td>
<td>179±20</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>110±8</td>
<td>105±10</td>
<td>100±11</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>48±16</td>
<td>52±11</td>
<td>54±20</td>
</tr>
<tr>
<td>Tissue factor activity</td>
<td>168±40</td>
<td>224±69*</td>
<td>191±40</td>
</tr>
</tbody>
</table>

*p<0.05.

smoked ≥10 cigarettes per day with a smoking history of ≥10 years, and untreated hyperlipidemic subjects (n=10) with total cholesterol ≥200 mg/dL and LDL cholesterol ≥100 mg/dL. Furthermore, a group of healthy volunteers (n=15) without the risk factors was also included to serve as a control group.

Study Design

Characteristics of the Study Population

Poorly controlled patients with DMT2 and hemoglobin A1c (HbA1c >7.5%) were selected for the study. While maintaining their present hypoglycemic therapies, they were randomized in a double-blind design into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for 3 months, as previously described.21 Troglitazone was given at a dose of 600 mg/d to the intensive group. BT and circulating TF activity were measured at baseline and 3 months after treatment. The repeated measurements allowed every patient to serve as his or her own control. Clinically significant improvement in glycemic control was defined as a reduction in HbA1c ≥0.5 percentage points. TF was determined after overnight fasting both at baseline and 3 months after treatment. The baseline characteristics of both groups are presented in Table 1; no significant differences between these groups were found in diabetes duration, concomitant medication, or presence of cardiovascular risk factors.

Assessment of Blood Thrombogenicity

The effect of glycemic control on BT was assessed at baseline and after 3 months of treatment as changes in the thrombus area using the Badimon perfusion chamber. The perfusion chamber and BT studies have been previously described.8,21–23

Statistical Analysis

Data are expressed as mean±SEM. Differences between the treatment groups were assessed using nonpaired Student’s t test or Mann-Whitney U test when distribution was not normal. Follow-up Pearson correlations between Δ scores were conducted. Finally, two-tailed significance level was set at <0.05. Statistical analyses were performed with SPS 10.01.

Results

Circulating TF Activity

Levels of circulating TF activity were determined using a modification of a previously described technique.10 The modified technique requires only 480 μL of plasma. Adjusted titration of phospholipid concentration for optimal TF activity was required because of the low plasma volume being used. The titration curve from 2.5 to 250 μmol/L of total phospholipids (30:70 phosphatidylcholine:phosphatidylserine) is presented in Figure 1. The concentration of 75 μmol/L of phospholipid gave optimal activity for typical plasma samples. A batch of pooled plasma obtained from 21 healthy volunteers and a separate batch of 6 pmol/L recombinant TF (Genentech) served as standardized controls of TF activity for all experiments. The interassay and intra-assay coefficients of variation were 10% and <5%, respectively.

Figure 1. To determine the concentration of phospholipid that yielded the optimum TF activity, various concentrations of phosphatidylcholine:phosphatidylserine (30%:70%) were added to the elution buffer and the resulting TF activity was measured.
Citrated plasma samples (480 μL) were mixed with 20 μL of Triton X-100 and centrifuged for 10 minutes (2000g at reverse transcriptase). The solubilized TF protein was captured by a polyclonal antibody immobilized to Affigel (BioRad; 0.25 mg polyclonal antibody TF per mL of Affigel). The rabbit polyclonal antibody anti-sTF was raised against the solubilized TF mutant (residues 1 to 218), encompassing most of the extracellular domain of wild-type human TF.24 TF was eluted from the gel by adding guanidine-HCl (5 mol/L), BSA (0.2%), n-octyl-β-D-glucopyranoside (100 mmol/L), and phospholipid mixture (75 μmol/L), all final concentrations. The eluate was dialyzed for at least 4 hours against HEPES-buffered saline (10 mmol/L HEPES, pH 7.4; 140 mmol/L NaCl). TF was assessed by adding factor X (150 mmol/L), factor VIIa (1 mmol/L), and calcium (5 mmol/L) and then periodically removing samples of the reacting mixture and storing them in EDTA. The concentration of factor Xa (FXa) in each removed sample was determined by adding a chromogenic substrate (Spectrozyme-Xa; American Diagnostica) and comparing the rate of change in absorbance (optical density 405 nm) to a standard curve obtained with known concentrations of FXa. Hence, circulating data are reported as the increase in the concentration of FXa per unit time (pmol/L per min). In control experiments, the omission of factor VIIa from the reaction mixture completely abolished FXa generation, and in separate experiments, preincubation of the dialyzed samples with an inhibitory anti-TF antibody resulted in a 91% inhibition in TF. In addition, standard curves performed with twice the normal volume of plasma and with serial dilutions of plasma showed a dose-dependent response in the measured levels of TF activity (r=0.94).

TF Activity and Blood Thrombogenicity in DM: Effect of Glycemic Improvement
DM was associated with significantly higher baseline levels of TF (371±161 versus 216±35 pmol/L per min FXa, P<0.0001) and BT (14 389±762 versus 11 354±7098 μm2/mm2, P<0.001) than the control group. To additionally investigate the effect of glycemic control, the patients with DM were separated into 2 groups based on their improvement in glycemic control (Figure 2). Improved glycemic control was defined as ≥0.5% reduction in HbA1c. The improvement in glycemic control was associated with a significant reduction in levels of circulating TF activity (362±161 versus 286±163 pmol/L per min FXa, P=0.0001). On the other hand, patients without glycemic improvement showed no change in TF activity (387±191 versus 354±221). Interestingly, these effects were independent of the treatment.

We have previously reported a similar pattern of BT in patients depending on whether they did or did not have improved glycemic levels.21 A significant reduction in thrombus formation was observed in the group with improved glycemic control (15 140±4963 versus 11 904±2927 μm2/mm2, P=0.002), whereas patients without improvement did not have any change in BT (14 236±2310 versus 15 362±3718 μm2/mm2; NS). Again, those changes were dependent on the glycemic improvement rather than the treatment received. Furthermore, glycemic control was a predictive variable for TF in T2DM as a group. Reduction in Hba1c after 3 months of treatment was positively correlated with reduction of TF (r=0.40, P=0.016). A positive correlation was also found between changes in BT and TF after 3 months of treatment (r=0.46, P=0.007).

Circulating TF Activity in Smoker Patients
Active smoking, despite 24 hours of being smoke-free, was associated with significantly higher levels of circulating TF activity than not smoking (224±69 versus 168±40 pmol/L per min FXa; P<0.05). Baseline levels of circulating TF in current smokers were significantly increased 2 hours after smoking 2 cigarettes (217±72 pmol/L versus 283±106 pmol/L per min FXa, P=0.003). There were no sex-related differences at baseline or after 2 hours (209±36 versus 221±78 pmol/L per min FXa at baseline and 255±90 versus 315±110 pmol/L per min FXa 2 hours after smoking). TF baseline levels showed a strong correlation with TF levels detected 2 hours after smoking (r=0.88). Despite the reduced
number of subjects involved in the group, a strong correlation ($r=0.76$, $P=0.010$) was observed between the average number of smoked cigarettes per subject and baseline (12 hours without smoking) levels of circulating TF activity.

Circulating TF Activity in Hyperlipidemic Patients
Circulating TF activity in hyperlipidemic subjects was significantly higher than in healthy donors ($237\pm63$ versus $194\pm40$ pmol/L per min FXa, $P=0.035$). Interestingly, despite the reduced number of subjects involved in this group, a significant correlation was observed between plasma levels of LDL cholesterol and circulating TF ($r=0.44$, $P<0.05$). In addition, an interesting trend, even though not statistically significant, was seen between TF and HDL cholesterol ($r^2=-0.32$).

Discussion
This study correlates increased levels of circulating TF activity associated with DM, hyperlipidemia, and smoking. These cardiovascular risk factors have been epidemiologically linked to a high incidence of atherothrombotic complications. Similar to the well-established concept of vulnerable high-risk atherosclerotic lesion, these observations bring to our attention the concept of a high-risk or “vulnerable” blood (procoagulant state?) associated with certain cardiovascular risk factors.16–21 High levels of circulating TF activity could be responsible for the observed increase in BT associated with these pathologic conditions. Furthermore, our observations provide evidence that the adequate management of hyperglycemia in T2DM significantly reduces the increased BT in these patients.21

Similar correlations between circulating TF activity and hyperlipidemia and smoking were obtained. These observations highlight the impact of certain cardiovascular risk factors on platelet and blood reactivity. The concept of high-risk blood is supported by pathological evidence of coronary thrombosis without plaque disruption. Patients showing only endothelial erosion were associated with DM, cigarette smoking, or an atherogenic lipid profile (high total cholesterol without plaque disruption). Patients had increased TF expression in aortic atherosclerotic lesions recently been reported that mice exposed to cigarette smoke had increased TF expression in aortic atherosclerotic lesions.20 By combining these observations with our own observations correlating the TF content of human atherosclerotic lesions and its thrombogenicity when exposed to flowing blood,5,8 we speculate that smoking may enhance circulating TF activity and BT.

Others authors have documented enhanced TF expression mediated by monocytes in the presence of platelets in patients with hypercholesterolemia, but they did not determine TF in the plasma.28 Hyperlipidemia is associated with the generation of oxidized LDL, macrophage, and monocyte activation and cell apoptosis. Such phenomena may generate TF released in the circulation as procoagulant particles.14,15 We have reported an increased BT in hyperlipidemic patients and normalization of the increased thrombogenicity after the normalization of plasma cholesterol levels by statin administration.23 More recently, it has been reported that lipid lowering by statin therapy has reduced TF expression and macrophage recruitment in atherosclerotic rabbits and reduced cholesterol-induced thrombogenicity.29,30

In conclusion, our data indicate the following: (1) Increased BT in poorly controlled T2DM seems to be related to plasma levels of a circulating pool of activatable TF activity; (2) improvements in glycemic control are associated with a reduction in plasma levels of circulating TF activity and BT; and (3) risk factors such as hyperlipidemia and smoking have a significant modulatory effect on plasma levels of circulating TF and BT. Therefore, the importance of an effective and global management of all of the existing risk factors on the prevention and treatment of cardiovascular diseases is clearly emphasized by these observations, showing a strong correlation between some cardiovascular risk factors and both increased TF activity and BT. Furthermore, the described circulating pool of TF activity could be the rationale for the development of specific inhibitors of the TF pathway for the prevention and treatment of thrombotic complications.

Acknowledgments
Supported by a grant from the Spanish Society of Cardiology, Madrid, Spain (to Dr Sambola) and the NIH SCOR on Thrombosis P50 HL 54469-07 to Drs Fuster, Nemerson, and Badimon.

References


Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity
Antonia Sambola, Julio Osende, James Hathcock, Michael Degen, Yale Nemerson, Valentin Fuster, Jill Crandall and Juan Jose Badimon

_Circulation._ 2003;107:973-977; originally published online February 10, 2003;
doi: 10.1161/01.CIR.0000050621.67499.7D
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/107/7/973

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/